Tyler Van Buren
Stock Analyst at TD Cowen
(1.71)
# 3,391
Out of 5,022 analysts
55
Total ratings
42.22%
Success rate
-2.23%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Initiates: Buy | n/a | $27.07 | - | 1 | Jul 22, 2025 | |
| CGON CG Oncology | Initiates: Buy | n/a | $42.85 | - | 1 | Jan 7, 2025 | |
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $15.09 | - | 2 | Dec 12, 2024 | |
| BHVN Biohaven | Maintains: Buy | $55 → $75 | $16.66 | +350.18% | 2 | Nov 13, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $17.31 | - | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | n/a | $27.48 | - | 1 | Sep 16, 2024 | |
| MRNA Moderna | Maintains: Hold | $70 → $60 | $26.25 | +128.57% | 6 | Sep 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | n/a | $2.87 | - | 1 | Aug 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | n/a | $9.42 | - | 1 | Aug 6, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,030 → $1,200 | $572.60 | +109.57% | 7 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $16.09 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $37.86 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $85 | $118.48 | -28.26% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $69.38 | -56.76% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $21.00 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $87.33 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $52.37 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $26.14 | +14.77% | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $56.50 | - | 1 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.50 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $31.72 | +120.68% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.54 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.41 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.93 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $10.39 | +2,065.54% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $9.66 | +8,957.97% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $9.18 | +335.73% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $13.85 | +116.61% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.62 | +9,563.39% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.51 | +3,211.26% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $2.38 | +1,160.50% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 → $200 | $4.59 | +4,257.30% | 1 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.10 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $20.11 | - | 1 | Aug 4, 2017 |
IDEAYA Biosciences
Jul 22, 2025
Initiates: Buy
Price Target: n/a
Current: $27.07
Upside: -
CG Oncology
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $42.85
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $15.09
Upside: -
Biohaven
Nov 13, 2024
Maintains: Buy
Price Target: $55 → $75
Current: $16.66
Upside: +350.18%
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $17.31
Upside: -
Oruka Therapeutics
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $27.48
Upside: -
Moderna
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $26.25
Upside: +128.57%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $2.87
Upside: -
Cartesian Therapeutics
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $9.42
Upside: -
Regeneron Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $572.60
Upside: +109.57%
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $16.09
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $37.86
Upside: -
Apr 26, 2024
Maintains: Buy
Price Target: $90 → $85
Current: $118.48
Upside: -28.26%
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $69.38
Upside: -56.76%
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $21.00
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $87.33
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $52.37
Upside: -
May 22, 2023
Initiates: Outperform
Price Target: $30
Current: $26.14
Upside: +14.77%
Feb 6, 2023
Initiates: Outperform
Price Target: n/a
Current: $56.50
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.50
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $31.72
Upside: +120.68%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.54
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $9.41
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $13.93
Upside: -
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $10.39
Upside: +2,065.54%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $9.66
Upside: +8,957.97%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $9.18
Upside: +335.73%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $13.85
Upside: +116.61%
Jun 29, 2020
Initiates: Overweight
Price Target: $60
Current: $0.62
Upside: +9,563.39%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.51
Upside: +3,211.26%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $2.38
Upside: +1,160.50%
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $4.59
Upside: +4,257.30%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $4.10
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $20.11
Upside: -